Article ID Journal Published Year Pages File Type
3063280 Journal of Clinical Neuroscience 2007 4 Pages PDF
Abstract

We report our experience, using mycophenolate mofetil (MyM) as an adjunctive immunosuppressive therapy in patients with severe, refractory and high dose steroid-dependant myasthenia gravis (MG). Five patients were commenced on MyM in addition to other immunosuppressive therapies. All had significant clinical improvement and no subsequent myasthenic crisis requiring intensive care unit admission. MyM was well tolerated and no serious adverse effects were observed. MyM is an effective adjunctive therapy for the treatment of severe, refractory and steroid-dependant MG in our experience.

Related Topics
Life Sciences Neuroscience Neurology
Authors
, , , ,